請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49807
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張正琪 | |
dc.contributor.author | Chuan-Chun Chou | en |
dc.contributor.author | 周傳鈞 | zh_TW |
dc.date.accessioned | 2021-06-15T11:49:40Z | - |
dc.date.available | 2019-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-12 | |
dc.identifier.citation | 1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK, Head and neck cancer. N Engl J Med 1993; 328: 184-94.
2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54. 3. Jatin P. Shah. Current concepts in management of oral cancer--surgery. Oral oncol. 2009; 45(4-5):394-401. 4. Parkin DM, Bray F, Ferlay J, Pisani P. Blobal cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. 5. Negri E, La Vecchia C, Franceschi, Tavani A. Attributable risk for oral cancer in Northern Italy. Cancer Epidemiol Biomarkers Prev. 1993; 2: 189-93. 6. Boyle P, MacFarlane GJ, Blot WJ, Chiesa F. European School of Oncology Advisory report to the European commission for the Europe Against Cancer program; oral carcinogenesis in Europe (review). Oral Oncol Eur J Cancer. 1995; 31B: 75-85. 7. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2004; 45: 309-316. 8. Wutzl A, Ploder CD, Kermer C, Millesi W, Ewers R, Klug C. Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg. 2007; 65: 255-60. 9. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3: 453-8. 10. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12: 895-904. 11. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350-5. 12. Orastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001; 345: 1890-900. 13. Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Amm Surg Oncol. 2008; 15: 915-22. 14. Gupta GP, Massague J. Cancer metastasis: binding a framework. Cell. 2006; 127; 679-95. 15. Cai C, Masumiya H, Weisleder N, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009; 11: 56-64. 16. Chuanxi Cai, Peihui Lin, Hua Zhu, et al. Zinc Binding to MG53 Protein Facilitates Repair of Injury to Cell Membranes. J Biol Chem. 2015; 290(22): 13830–13839. 17. Liu J, Zhu H, Zheng Y, et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol. 2015; 80: 10-9. 18. Cao CM, Zhang Y, Weisleder N, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010; 121(23): 2565-74. 19. He B, Tang RH, Weisleder N, et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters. Mol Ther. 2012; 20(4): 727-35. 20. Jesper Nylandsted. Plasma membrane repair provides a new strategy for targeting metastatic cancer cells. Cancer Cell & Microenvironment. 2015; 2: e446. 21. Cai C, Masumiya H, Weisleder N, et al. MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem. 2009; 284(5): 3314-22. 22. Weisleder N, Takeshima H, Ma J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair. Commun Integr Biol. 2009; 2(3): 225-6. 23. Jae-Sung Yi, Jun Sub Park, Young-Mi Ham, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signaling. Nat Commun. 2013; 4: 2354. 24. Steinhardt RA, Bi G, Alderton JM. Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science. 1994; 263(5145):390-3. 25. Miyake K, McNeil PL. Vesicle accumulation and exocytosis at sites of plasma membrane disruption. J Cell Biol. 1995; 131(6 Pt 2):1737-45. 26. Yi JS, Park JS, Ham YM, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signaling. Nat Commun. 2013;4:2354. 27. Li H, Duann P, Lin PH, et al. Modulation of wound healing and scar formation by MG53 protein-mediated cell membrane repair. J Biol Chem. 2015; 290(40):24592-603. 28. Keiko Ozato, Dong-Mi Shin, Tsung-Hsien Chang, et al. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008; 8(11): 849–860. 29. Bo He, Ru-hang Tang, Noah Weisleder, et al. Enhancing Muscle Membrane Repair by Gene Delivery of MG53 Ameliorates Muscular Dystrophy and Heart Failure in δ-Sarcoglycan-deficient Hamsters. Mol Ther. 2012;20(4):727-35. 30. Ruisheng Song, Wei Peng, Yan Zhang, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 201; 494(7437):375-9. 31. Feng-Chiao Tsai, Guan-Hung Kuo, Shu-Wei Chang, et al. Ca2+ signaling in cytoskeletal reorganization, cell migration, and cancer metastasis. Biomed Res Int. 2015; 2015: 409245. 32. Déliot N, Constantin B. Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration. Biochim Biophys Acta. 2015; 2512-22. 33. Ravid T, Heidinger JM, Gee P, et al. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem. 2004; 279(35):37153-62. 34. Gr?vdal LM, Stang E, Sorkin A, et al. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004; 300(2):388-95. 35. Han W, Zhang T, Yu H, et al. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 2006; 5(10):1361-8. 36. Kadera BE, Toste PA1, Wu N, et al. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. Clin Cancer Res. 2015; 21(1):157-65. 37. Wei TT, Lin YC, Lin PH, et al. Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. Oncotarget. 2015; 6(14):12481-92. 38. Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Dhanya Haridas, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1): 15–31. 39. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001; 8(1):11-31. 40. Gross A, Niemetz-Rahn A, Nonnenmacher A, et al. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol. 2015; 10(1):77-84. 41. Ribeiro FA, Noguti J, Oshima CT, Ribeiro DA. Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res. 2014; 34(4):1547-52. 42. Masuda H, Zhang D, Bartholomeusz C, Doihara H. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136(2):331-45. 43. Da Cunha Santos G1, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49-69. 44. Markman B, Javier Ramos F, Capdevila J, et al. EGFR and KRAS in colorectal cancer. Adv Clin Chem. 2010;51:71-119. 45. Hsu CY, Hurwitz DR, Mervic M, Zilberstein A. Autophosphorylation of the intracellular domain of the epidermal growth factor receptor results in different effects on its tyrosine kinase activity with various peptide substrates. Phosphorylation of peptides representing Tyr (P) sites of phospholipase C-gamma. J Biol Chem. 1991; 266(1):603-8. 46. Guo L, Kozlosky CJ, Ericsson LH. Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom. 2003; 14(9):1022-31. 47. Sato K. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci. 2013; 14(6):10761-90. 48. Friedman LM, Rinon A, Schechter B, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A. 2005; 102(6):1915-20. 49. Oliveira S, Schiffelers RM, Van der Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010; 145(2):165-75. 50. Lauand C, Rezende-Teixeira P, Cortez BA, et al. Independent of ErbB1 gene copy number, EGF stimulates migration but is not associated with cell proliferation in non-small cell lung cancer. Cancer Cell Int. 2013; 13(1):38. 51. Nishimura Y, Bereczky B, Ono M. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines. Histochem Cell Biol. 2007; 127: 541-553. 52. Mayumi Naramura, Scott Nadeau, Bhopal Mohapatra, et al. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget. 201; 2(3): 245-50. 53. de Melker AA, van der Horst G, Calafat J, et al. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci. 2001; 114(Pt 11): 2167-78. 54. Bill HM, Knudsen B, Moores SL, Muthuswamy SK, et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol. 2004; 24(19):8586-99. 55. Chen CY, Jan CI, Lo JF, Yang SC, et al. Tid1-L inhibits EGFR signaling in lung adenocarcinoma by enhancing EGFR Ubiquitinylation and degradation. Cancer Res. 2013; 73(13):4009-19. 56. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011; 11(8):609-18. 57. Chen YF, Chen YT, Chiu WT, et al. Remodeling of calcium signaling in tumor progression. J Biomed Sci. 2013; 20:23. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49807 | - |
dc.description.abstract | 目的:我們的目標在於探討三分膜體包含蛋白72號在口腔鱗狀上皮細胞癌進程中所扮演的角色,並將其與臨床上的資料以及病人的存活率藉由統計方式比較其相關性。除此之外,也針對其詳細的調控機轉作進一步的探究及闡述。
實驗設計:利用SAS、CA922、HSC3、Cal27以及TW2.6五株口腔鱗狀上皮細胞癌細胞株來探討三分膜體包含蛋白72號表現量被小髮夾型核糖核酸抑制或轉殖表現質體過度表現後的移行能力、浸襲能力以及生長能力是否有受到影響。在細胞移動能力的測定上,我們利用博登細胞移行器實驗來做分析;生長能力則是使用细胞存活率分析做測定。動物模式實驗是利用原位種植的技術,使重症聯合免疫缺陷小鼠的頰黏膜生成口腔鱗狀上皮細胞癌腫瘤,並檢驗其淋巴轉移情形和動物存活率。藉由核醣核酸微列陣與GESA分析主要訊息傳遞路徑,並使用pulse-chase assay及泛素化WB-IP分析下游因子與三分膜體包含蛋白72號調控之機制。 結果:臨床上顯示三分膜體包含蛋白72號在晚期腫瘤以及具有淋巴轉移的腫瘤中呈現顯著提升的表現量(P < 0.05),並且與病人存活率具有統計意義的相關(P < 0.05)。細胞實驗中發現抑制SAS以及CA922細胞中三分膜體包含蛋白72的表現量會使細胞移行能力(P < 0.05)和浸襲能力下降(P < 0.05)但不會改變生長能力。在動物實驗方面,三分膜體包含蛋白72號被抑制的組別其淋巴轉移能力有顯著地下降,而其存活率則呈現顯著地上升 (P < 0.01)。經由核醣核酸微列陣分析以及基因組富集分析找到下游分子為表皮生長因子受體,三分膜體包含蛋白72號被抑制時可觀察到表皮生長因子受體的蛋白表現量明顯下降,但不影響RNA之表現。經由pulse-chase assay以及泛素化WB-IP實驗發現三分膜體包含蛋白72號是藉由後轉譯修飾的方式調控表皮生長因子受體使其不被泛素化降解。藉由過度表現該下游蛋白則可顯著恢復細胞因三分膜體包含蛋白72號表現量被抑制而造成的移動能力下降 (P < 0.05)。雖然在細胞膜修復機制中,三分膜體包含蛋白72號會招募鈣離子,但是在促進癌症進程時卻不與鈣離子有關聯。 結論:本論文確認三分膜體包含蛋白72號可為臨床口腔鱗狀上皮細胞癌病患之惡化預後因子,該基因能增加口腔鱗狀上皮癌之移行、浸襲能力,及實驗動物之淋巴轉移現象。分子機制為藉由後轉譯修飾作用以抑制表皮生長因子受體泛素化降解,以促進癌症進程。 | zh_TW |
dc.description.abstract | Purpose: We aim to examine the roles of tripartite motif-containing protein 72 (TRIM72) in OSCC progression, and to correlate it with patient clinical status and survival rate. Underlying mechanism is also investigated.
Experimental design: Oral cancer cell lines, including SAS, CA922, HSC3, Cal27, and TW2.6, were used as in vitro models to investigate cell phenotypes, such as invasion, migration, and proliferation by ectopic expressed-TRIM72 or silenced-TRIM72 (shTRIM72) plasmids transfection. Boyden chamber assay was performed to check migration and invasion abilities. Proliferation ability was identified by MTT assay. Mice were injected with shTRIM72 or vector control SAS cells to examine lymph node metastasis and survival rate. mRNA microarray of stable transfectants elucidated the downstream signaling. EGFR protein pulse-chase assay and ubiquitination WB-IP analysis are used in this study. Results: Clinical data revealed that TRIM72 expression was related to OSCC patient TNM stage, lymph node metastasis, and survival rate (P < 0.05). Transiently transfected SAS and CA922 cells with shTRIM72 plasmids significantly reduced migration and invasion ability (P < 0.05), but did not alter proliferation ability, compared to vector control cells. Furthermore, we established shTRIM72-stable transfectants in SAS cells, and found that silenced-TRIM72 could significantly down-regulate migration and invasion (P < 0.05). In animal study, lymph node metastasis ability was blocked in orthotopic-injected shTRIM72-stable transfectants, and the survival rate was increased compared to vector control clone (P < 0.05). Additionally, we performed high-throughput mRNA microarray analysis and GSEA analysis to identify epidermal growth factor receptor (EGFR) a crucial downstream pathway. TRIM72-enhanced EGFR expression through inhibited ubiquitin-related degradation, which prolonged the half-life of EGFR. Transfected with EGFR expression plasmid could completely restore migration and invasion abilities in shTRIM72 stable transfectants (P < 0.05). Although TRIM72 recruits Ca2+ to repair membrane damage, it enhanced OSCC progression in a Ca2+-independent manner. Conclusions: TRIM72 was a poor prognostic factor in OSCC patents clinically. TRIM72 enhanced invasion and migration ability in OSCC cells, and increased lymph node metastasis in vivo. TRIM72 promoted EGFR expression through inhibited ubiquitin-related degradation in post-translational regulation to cause OSCC progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:49:40Z (GMT). No. of bitstreams: 1 ntu-105-R03450015-1.pdf: 1843585 bytes, checksum: 101b4f1699ad09661597263b300ef327 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | Abstract in Chinese…………………………………………………………….………i
Abstract in English……………………………………………………………….……ii Contents……………………………………………………………………...………..iv Introduction…………………………………………………………………....………1 Materials and Methods……………………………………………………….......……5 Results……………………………………………………………………...……...…14 I. TRIM72 played as a poor prognostic factor in OSCC patients. …………………………………………...…………………14 II. TRIM72 enhanced cell migration and invasion ability in OSCC cells………………………………………………...…………………14 III. Knocked-down TRIM72 declined lymph node metastatic ability in orthotopic-injected OSCC mouse model……………………………..16 IV. rTRIM72 protein treatment enhanced invasion ability in a Ca2+-independent manner………………………………...…………..……17 V. EGFR was an important downstream effector in TRIM72-enhanced OSCC progression……………………………...……………….……18 VI. TRIM72 declined the ubiquitinated-EGFR in OSCC cells……………………..……………………...………….…….……19 Discussion…………………..……………………………………………...……...…21 Figures…………………..………………..………………………………...……...…24 Figure 1. TRIM72 played as a poor prognostic factor in OSCC patients..……………..………………..……………………………………...24 Figure 2. TRIM72 enhanced cell migration and invasion ability in OSCC cells. ..……………..………………..………………………………………...26 Figure 3. knocked-down TRIM72 declined lymph node metastatic ability in orthotopic-injected OSCC mouse model……………..………….…………...29 Figure 4. rTRIM72 protein treatment enhanced invasion ability in a Ca2+-independent manner. ..…………….…..……………………………………...30 Figure 5 EGFR was an important downstream effector in TRIM72-enhanced OSCC progression. ..……….………..………………………………..……...31 Figure 6. The ubiquitination levels of EGFR was decreased with TRIM72 expression in OSCC cells. ..……………..…………………………………...33 Supplemental figures..……….………..………………………………………..…….35 Supplement Figure 1. Knockdown of TRIM72 didn’t alter cell proliferation in SAS and CA922 cells. .………..…………………………………………..…35 Supplement Figure 2. TRIM72 overexpression didn’t alter cell proliferation in Cal27 cells.………..………………………...……………………………..…36 References.………..………………………………………..………………………...37 | |
dc.language.iso | en | |
dc.title | 三分膜體包含蛋白72號於口腔癌進程之角色 | zh_TW |
dc.title | The Roles of Tripartite Motif-containing Protein 72 in Oral Cancer Progression | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 俞松良,郭彥彬 | |
dc.subject.keyword | 口腔鱗狀上皮細胞癌,移行,浸襲,三分膜體包含蛋白72號,表皮生長因子受體, | zh_TW |
dc.subject.keyword | oral squamous cell carcinoma,migration,invasion,TRIM72,EGFR, | en |
dc.relation.page | 44 | |
dc.identifier.doi | 10.6342/NTU201602178 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。